This intervention includes the introduction of the Prostate Cancer Working Group (PCWG )Smart PSA Screening Guidelines and implementation of patient navigation/ care coordination for men with elevated PSA (\>4.0 ng/mL). The guidelines include: 1. What age to start? 2. How often to repeat screening? 3. What age to stop? 4. What PSA threshold should trigger a biopsy referral?
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of PSA tests ordered per number of clinical encounters 12 months prior to the intervention
Timeframe: Monthly for 12 months prior to intervention
Number of PSA tests ordered per number of clinical encounters during the intervention
Timeframe: Monthly for 12 months during intervention
Number of PSA levels categorized as <4.0, 4.0-10.0 and >10.0 12 month prior to the intervention
Timeframe: Monthly for 12 months prior to intervention
PSA levels categorized as <4.0, 4.0-10.0 and >10.0 during the intervention
Timeframe: Monthly for 12 months during intervention
Number of Urology referrals 12 months prior to the intervention
Timeframe: 12 months prior to intervention
Number of Urology referrals during the intervention
Timeframe: 12 months after intervention
Number of prostate biopsies performed using the risk levels of the National Comprehensive Cancer Network (NCCN) of very low, Favorable intermittent, Unfavorable intermittent, High, very high 12 months prior to the intervention
Timeframe: 12 months prior to the intervention
Number of prostate biopsies performed using the risk levels of the National Comprehensive Cancer Network (NCCN) of very low, Favorable intermittent, Unfavorable intermittent, High, very high during the intervention
Timeframe: 12 months after the intervention
Number of prostate biopsy complications 12 months prior to the intervention
Timeframe: 12 months prior to intervention
Number of prostate biopsy complications during the intervention
Timeframe: 12 months after intervention
Benefit and harm analysis 12 months prior to the intervention
Timeframe: 12 months prior to intervention
Benefit and harm analysis 12 months prior to the intervention
Timeframe: 12 months prior to intervention
Benefit and harm analysis 12 months prior to the intervention
Timeframe: 12 months prior to intervention
Benefit and harm analysis 12 months prior to the intervention
Timeframe: 12 months prior to intervention
Benefit and harm analysis during the intervention
Timeframe: 12 months after intervention
Benefit and harm analysis during the intervention
Timeframe: 12 months after intervention
Benefit and harm analysis during the intervention
Timeframe: 12 months after intervention
Benefit and harm analysis during the intervention
Timeframe: 12 months after intervention
Number of PCPs that have confidence in discussing prostate issues 12 months prior to the intervention
Timeframe: 12 months prior to intervention
Number of PCPs that have confidence in discussing prostate issues during the the intervention
Timeframe: 12 months after intervention
Number of patients referred to specialty care 12 months prior to patient navigation/ care coordination
Timeframe: 12 months prior to intervention
Number of patients referred to specialty care through patient navigation/ care coordination during the intervention
Timeframe: 12 months after intervention